Axion BioSystems
Biotechnology ResearchGeorgia, United States51-200 Employees
Axion BioSystems develops live-cell analysis tools that enable continuous, noninvasive monitoring of in vitro cell models on benchtops or inside incubators. Its offerings support research into disease mechanisms in neurology and cardiology and are used to advance immunotherapies and antivirals; the company serves academic, biotechnology, and pharmaceutical labs and is based in Atlanta, Georgia, with a global workforce of more than 180 people. Since its early work in live-cell analysis, Axion has expanded its offerings to provide real-time, label-free monitoring with scalable throughput. In 2026 the company announced the acquisition of intellectual property and assets from CytoTronics, signaling continued expansion of its technology portfolio.